Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Over the past two years, Eli Lilly has earned approval for such products as Alzheimer's disease (AD) treatment Kisunla, ulcerative colitis drug Omvoh, cancer medicine Jaypirca, and eczema therapy ...

I think Eli Lilly and Company's stock correction may ... I see from indirect signs that the overall demand for LLY's key products — Zepbound and Mounjaro — keeps rising in the US.

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus. Here's why they view Eli Lilly (NYSE ...

Eli Lilly and Company discovers ... It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for ...

Eli Lilly has said it is seeking permission ... The plant will be used to "support increased demand for existing Lilly products and play a key role in bringing Lilly's robust clinical pipeline ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.